



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 31/00		(11) International Publication Number: WO 00/16755
	A2	(43) International Publication Date: 30 March 2000 (30.03.00)
(21) International Application Number: PCT/EP99/05886		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TI, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TI, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 17 September 1999 (17.09.99)		
(30) Priority Data: 9820420.9 18 September 1998 (18.09.98) GB		
(71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).		
(72) Inventors; and		
(75) Inventors/Applicants (for US only): BROWN, Nathaniel, A, [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US), CONDREAY, Lynn, D, [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US), GRAY, Douglas, Fraser [GB/GB]; Glaxo Wellcome plc, 891-995 Greenford Road, Greenford, Middlesex UB6 0HE (GB), RUBIN, Marc [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US).		
(74) Agent: TEUTEN, Andrew, J; Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).		
(54) Title: <u>ANTIVIRAL COMBINATIONS</u>		
(57) Abstract		
<p>The present invention relates to therapeutic combinations comprising (2R, cis)-4-amino-1-(2-hydroxymethyl-1, 3-oxathiolan-5-yl)-pyrimidin-2-one (lamivudine) and a second therapeutic agent selected from (9-[(R)-2-(phosphonomethoxy) ethyl]adenine, (PMEA or adefovir) and bis(pivaloyloxymethyl) (9-(R)-2-(phosphonomethoxy)ethyl)adenine, (the oral prodrug of PMEA, adefovir dipivoxil) which have anti-hepatitis B virus (HBV) activity. The present invention is also concerned with pharmaceutical compositions containing said combinations and their use in the treatment of HBV infections including infections with HBV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors.</p>		